Plain-English translation of NCT07109700 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 2 Diabetes research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called HDM1005 to see if it can help people with type 2 diabetes control their blood sugar better. The study will compare four different doses of HDM1005 against a placebo (inactive injection) and against dulaglutide, an already-approved diabetes medication. Researchers want to learn if this new treatment works well and is safe for people whose blood sugar remains too high despite diet, exercise, or taking metformin.
Many people with type 2 diabetes struggle to control their blood sugar with lifestyle changes and existing medications alone. This trial explores whether this new medication could offer another treatment option to help more people reach their blood sugar goals.
You likely qualify if…
You likely don't qualify if…
You will have a 2-week screening period to confirm you qualify, followed by 20 weeks of treatment where you'll receive injections under the skin once weekly and visit the clinic regularly for blood tests and health checks. After finishing the injections, you'll have a 4-week follow-up period with one final visit 28 days later. Overall, the study lasts about 6.5 months. You'll be randomly assigned to receive one of four doses of the new medication, a placebo, or an already-approved diabetes medication so researchers can compare how well they work.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
China